This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakamura, J. L. Articles by Pieper, R. O. Search for Related Content PubMed PubMed Citation Articles by Nakamura, J. L. Articles by Pieper, R. O.

S6K1 Plays a Key Role in Glial Transformation

Departments of ¹ Radiation Oncology and ² Neurological Surgery, University of California, San Francisco, California

Requests for reprints: Jean L. Nakamura, Department of Radiation Oncology, University of California, San Francisco, 505 Parnassus Avenue, Long Hospital L-75, San Francisco, CA 94143. Phone: 415-353-9694; Fax: 415-353-9883; E-mail: jnakamura{at}radonc.ucsf.edu.

Key Words: mTOR • S6 kinase • transformation

The mammalian target of rapamycin (mTOR) is a nutrient and ATP sensor suggested to play an important role in tumorigenesis, particularly in the setting of PTEN loss or activated Akt/PKB. Of mTOR's two known effectors, eIF4E has been implicated in tumorigenesis, whereas the role of S6 kinase (S6K1) in transformation is less understood. To assess the contribution of S6K1 to the transformed phenotype, we pharmacologically and genetically manipulated the mTOR-S6K pathway in glioma cells and monitored its effects on growth in soft agar, a hallmark of cellular transformation, and also assessed in vivo intracranial growth. Anchorage-independent growth by HRas^V12-transformed human astrocytes as well as by U251 and U373 human glioma cells was inhibited by pharmacologic mTOR inhibition. Similarly, short hairpin RNA–mediated suppression of mTOR also reduced anchorage-independent growth of glioma cell lines. Expression of wild-type eIF4E in rapamycin-treated E6/E7/hTert/HRas^V12 and U373 cells failed to rescue colony formation, although expression of wild-type S6K1 or rapamycin-resistant S6K1 in rapamycin-treated U373 and U251 provided partial rescue. Consistent with the latter observation, small interfering RNA–mediated suppression of S6K1 in HRas^V12-transformed human astrocytes, U251, and U373 cells resulted in a significant loss of anchorage-independent growth. Furthermore, we found that in vivo short hairpin RNA–mediated suppression of S6K1 in HRas^V12-transformed human astrocytes reduced intracranial tumor size, in association with reduced tumor levels of phosphorylated ribosomal protein S6. These findings implicate the mTOR-S6K pathway as a critical mediator of glial cell transformation. [Cancer Res 2008;68(16):6516–23]

This article has been cited by other articles:

				D. Guo, I. J. Hildebrandt, R. M. Prins, H. Soto, M. M. Mazzotta, J. Dang, J. Czernin, J. Y.-J. Shyy, A. D. Watson, M. Phelps, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis PNAS, August 4, 2009; 106(31): 12932 - 12937. [Abstract] [Full Text] [PDF]

				S. P. Narayanan, A. I. Flores, F. Wang, and W. B. Macklin Akt Signals through the Mammalian Target of Rapamycin Pathway to Regulate CNS Myelination J. Neurosci., May 27, 2009; 29(21): 6860 - 6870. [Abstract] [Full Text] [PDF]

				F. Meric-Bernstam and A. M. Gonzalez-Angulo Targeting the mTOR Signaling Network for Cancer Therapy J. Clin. Oncol., May 1, 2009; 27(13): 2278 - 2287. [Abstract] [Full Text] [PDF]